First Patient Dosed in Phase 1/2 Trial of FLX475 in Breast, Other Advanced Cancers
News
The first patient has been dosed in a Phase 1/2 trial evaluating FLX Bio’s investigational therapy, FLX475, alone and in combination with the PD-1 inhibitor Keytruda (pembrolizumab), as a therapy for triple ... Read more